e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Novel issues in the treatment and control of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma
I. Litvinova, S. Ovcharenko, V. Makolkin (Moscow, Russian Federation)
Source:
Annual Congress 2007 - Novel issues in the treatment and control of asthma
Session:
Novel issues in the treatment and control of asthma
Session type:
Thematic Poster Session
Number:
562
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Litvinova, S. Ovcharenko, V. Makolkin (Moscow, Russian Federation). Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma. Eur Respir J 2007; 30: Suppl. 51, 562
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 294s
Year: 2005
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016
Year: 2017
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF?
Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD
Year: 2009
Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function
Source: International Congress 2018 – Cardiovascular morbidities in COPD
Year: 2018
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Year: 2017
Impact of inhaled corticosteroids in patients with cardiovascular disease
Source: Eur Respir Monogr 2020; 88: 251-263
Year: 2020
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD
Source: Eur Respir J 2010; 35: 1003-1021
Year: 2010
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
The risk of cardiovascular disease associated with asthma may be mediated by short-acting β
2
-agonists
Source: Annual Congress 2008 - Epidemiology of asthma and allergy
Year: 2008
The impact of preventive treatment with long-acting β
2
adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma
Source: Annual Congress 2009 - Epidemiology of atopy and asthma
Year: 2009
The risk of hyperkalemia in COPD and asthma patients
Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases
Year: 2019
Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD
Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity
Year: 2011
Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 453s
Year: 2007
Use of metoprolol succinate in patients with cardiovascular diseases associated with asthma or chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 502s
Year: 2006
Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Coexistence of cardiovascular diseases in patients with COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept